Perioperative use of β-blockers in cardiac and noncardiac surgery.
Where this comes from
- Record sourced from PubMed, PMID 26010637.
- Also identified by DOI 10.1001/jama.2015.1883.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CLINICAL QUESTION: Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery? BOTTOM LINE: In cardiac surgery, β-blockers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arrhythmias. In noncardiac surgery, β-blockers are associated with a possible increase in mortality and strokes, a lower incidence of acute myocardial infarctions (AMIs) and SVTs, and an increase in bradycardia and hypotension. If tolerated, long-term β-blocker treatment should be continued perioperatively, whereas the decision to start a β-blocker should be individualized, weighing risks and benefits.